137 related articles for article (PubMed ID: 26474454)
1. Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.
Prenen H; Smeets D; Mazzone M; Lambrechts D; Sagaert X; Sciot R; Debiec-Rychter M
Oncotarget; 2015 Nov; 6(34):36418-25. PubMed ID: 26474454
[TBL] [Abstract][Full Text] [Related]
2. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells.
Kunze K; Spieker T; Gamerdinger U; Nau K; Berger J; Dreyer T; Sindermann JR; Hoffmeier A; Gattenlöhner S; Bräuninger A
Cancer Res; 2014 Nov; 74(21):6173-83. PubMed ID: 25252913
[TBL] [Abstract][Full Text] [Related]
3. Recurrent PTPRB and PLCG1 mutations in angiosarcoma.
Behjati S; Tarpey PS; Sheldon H; Martincorena I; Van Loo P; Gundem G; Wedge DC; Ramakrishna M; Cooke SL; Pillay N; Vollan HKM; Papaemmanuil E; Koss H; Bunney TD; Hardy C; Joseph OR; Martin S; Mudie L; Butler A; Teague JW; Patil M; Steers G; Cao Y; Gumbs C; Ingram D; Lazar AJ; Little L; Mahadeshwar H; Protopopov A; Al Sannaa GA; Seth S; Song X; Tang J; Zhang J; Ravi V; Torres KE; Khatri B; Halai D; Roxanis I; Baumhoer D; Tirabosco R; Amary MF; Boshoff C; McDermott U; Katan M; Stratton MR; Futreal PA; Flanagan AM; Harris A; Campbell PJ
Nat Genet; 2014 Apr; 46(4):376-379. PubMed ID: 24633157
[TBL] [Abstract][Full Text] [Related]
4. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
[TBL] [Abstract][Full Text] [Related]
5. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.
Murali R; Chandramohan R; Möller I; Scholz SL; Berger M; Huberman K; Viale A; Pirun M; Socci ND; Bouvier N; Bauer S; Artl M; Schilling B; Schimming T; Sucker A; Schwindenhammer B; Grabellus F; Speicher MR; Schaller J; Hillen U; Schadendorf D; Mentzel T; Cheng DT; Wiesner T; Griewank KG
Oncotarget; 2015 Nov; 6(34):36041-52. PubMed ID: 26440310
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
7. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib.
Silva E; Gatalica Z; Vranic S; Basu G; Reddy SK; Voss A
Breast J; 2015; 21(2):205-7. PubMed ID: 25639617
[No Abstract] [Full Text] [Related]
8. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis-related gene mutations drive a subset of angiosarcomas.
Cancer Discov; 2014 May; 4(5):OF18. PubMed ID: 24795022
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the PTEN gene in a human hepatic angiosarcoma.
Tate G; Suzuki T; Mitsuya T
Cancer Genet Cytogenet; 2007 Oct; 178(2):160-2. PubMed ID: 17954274
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma.
Wang G; Wu M; Durham AC; Radaelli E; Mason NJ; Xu X; Roth DB
PLoS One; 2020; 15(3):e0229728. PubMed ID: 32210430
[TBL] [Abstract][Full Text] [Related]
12. Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.
Zhrebker L; Cherni I; Gross LM; Hinshelwood MM; Reese M; Aldrich J; Guileyardo JM; Roberts WC; Craig D; Von Hoff DD; Mennel RG; Carpten JD
BMC Cancer; 2017 Jan; 17(1):17. PubMed ID: 28056866
[TBL] [Abstract][Full Text] [Related]
13. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
14. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
15. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib therapy for melanoma patients with KIT mutations.
Minor DR; Kashani-Sabet M; Garrido M; O'Day SJ; Hamid O; Bastian BC
Clin Cancer Res; 2012 Mar; 18(5):1457-63. PubMed ID: 22261812
[TBL] [Abstract][Full Text] [Related]
17. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
18. PLCG1 mutations in cutaneous T-cell lymphomas.
Vaqué JP; Gómez-López G; Monsálvez V; Varela I; Martínez N; Pérez C; Domínguez O; Graña O; Rodríguez-Peralto JL; Rodríguez-Pinilla SM; González-Vela C; Rubio-Camarillo M; Martín-Sánchez E; Pisano DG; Papadavid E; Papadaki T; Requena L; García-Marco JA; Méndez M; Provencio M; Hospital M; Suárez-Massa D; Postigo C; San Segundo D; López-Hoyos M; Ortiz-Romero PL; Piris MA; Sánchez-Beato M
Blood; 2014 Mar; 123(13):2034-43. PubMed ID: 24497536
[TBL] [Abstract][Full Text] [Related]
19. Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2.
Przygodzki RM; Finkelstein SD; Keohavong P; Zhu D; Bakker A; Swalsky PA; Soini Y; Ishak KG; Bennett WP
Lab Invest; 1997 Jan; 76(1):153-9. PubMed ID: 9010458
[TBL] [Abstract][Full Text] [Related]
20. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
